glp 1 gip agonist GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Main physiological actions of the

To illustrate these interactions, Figure 2 is presented below, and highlights points of convergence between underexplored peptides and established incretin pathways

The next phase is not one drug

Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the idiopathic intracranial hypertension weight trial (IIH: WT) protocol

HbA1C reductions ranged from 1.2% to 1.8% depending on dose and baseline glycemia

An important note: Zepbound has been approved for sleep apnea and Wegovy for cardiovascular risk, with weight loss as a side benefit

Marx N, et al